Gastric Cancer Connect
  • Saved

18h

Did you know?

HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma — defined as IHC 3+ or IHC 2+/ISH+ — affects 15–20% of patients with advanced disease. The KEYNOTE-811 Phase 3 trial (n=698) demonstrated that adding PD-1 checkpoint inhibition to trastuzumab plus chemotherapy significantly improved overall survival to 20.0 months vs. 16.8 months with placebo (HR 0.81; p=0.0093), representing the first OS benefit in HER2-positive gastric cancer beyond trastuzumab alone. The benefit was most pronounced in patients with combined positive score (CPS) ≥1.

NCCN Guidelines
Discussion question

How are you incorporating combined HER2 and PD-L1 biomarker assessment into your frontline treatment planning for gastric/GEJ adenocarcinoma — and how does CPS scoring influence your therapeutic sequencing decisions?

  • 18h
    A whopping 3 months (13 weeks) additional survival is not clinically meaningful for a lot of patients.
  • Saved

5d
Role of non-animal 3D models in H. pylori associated gastric carcinogenesis: Insights and future perspectives. - PubMed

Role of non-animal 3D models in H. pylori associated gastric carcinogenesis: Insights and future perspectives. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42603543

Discover how 3D gastric organoids surpass traditional models, enhancing understanding of gastric cancer's complexity and aiding in drug response prediction.


Gastric organoids surpass 2D cultures and animal models by mirroring tumour architecture, aiding research in gastric cancer heterogeneity and drug response prediction.

  • Saved

1w
Comprehensive Computed Tomography Evaluation of Gastric Cancer: 2026 Consensus Recommendation From the Korean Society of Abdominal Radiology. - PubMed

Comprehensive Computed Tomography Evaluation of Gastric Cancer: 2026 Consensus Recommendation From the Korean Society of Abdominal Radiology. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42551871

Explore new guidelines for standardized CT imaging in gastric cancer, focusing on improved staging, re-staging after chemotherapy, and risk-stratified postoperative surveillance.


The Korean Society of Abdominal Radiology's guidelines improve gastric cancer CT staging accuracy through standardized protocols, developed via a modified Delphi process, including T, N, M staging recommendations.

  • Saved

2w
HER2-directed therapy in advanced gastric and gastroesophageal junction adenocarcinoma: evolving combinations and sequencing strategies

HER2 overexpression occurs in 15–20% of advanced gastric and gastroesophageal junction (GEJ) adenocarcinomas. Anti-HER2 monoclonal antibody plus fluoropyrimidine/platinum chemotherapy established the first-line standard, demonstrating significant overall survival benefit in the pivotal phase 3 trial.

A HER2-directed antibody-drug conjugate (ADC), comprising an anti-HER2 antibody, cleavable linker, and topoisomerase I inhibitor payload, demonstrated an objective response rate of 41.8% in heavily pretreated HER2-positive advanced gastric/GEJ cancer (DESTINY-Gastric02). Its bystander effect may confer activity across varying HER2 expression levels. Key clinical challenges include HER2 IHC interobserver variability, intratumoral HER2 heterogeneity, acquired resistance, and ADC-associated toxicities including interstitial lung disease. VEGFR2-targeted antibody combinations remain relevant in HER2-negative or post-progression settings.

Gastrointestinal oncologists, medical oncologists, and pathologists managing HER2-positive advanced gastric/GEJ adenocarcinoma will benefit from discussion on HER2 testing, sequencing of HER2-directed therapies, resistance mechanisms, and ADC-related toxicity management.

How do you approach HER2 re-testing and re-biopsy decisions in gastric/GEJ patients progressing on first-line HER2-directed therapy, and how does HER2 heterogeneity influence your sequencing strategy? What monitoring protocols have you implemented for ADC-related toxicities, particularly interstitial lung disease, in patients with advanced gastric/GEJ cancer?

  • 2w
    I approach HER2 retesting selectively at progression, particularly when a patient is being considered for another HER2-directed therapy, because gastric/GEJ tumors can show substantial intratumoral heterogeneity and HER2 expression may Show More
  • Saved

2w
Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases. - PubMed

Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42538553

Explore how infectious and non-communicable diseases affect oncology and the potential for integrated cancer care strategies.


The study highlights the impact of infectious and non-communicable diseases in oncology, advocating for integrated cancer care strategies.